NCT03381417 - Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients. | Biotech Hunter

Enrollment

128

Participants

Timeline

Start Date

October 6, 2016

Primary Completion Date

November 6, 2017

Study Completion Date

November 6, 2017

Conditions

Breast Cancer Female

Interventions

DRUG

pegcyte

Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.

DRUG

Neulastim

Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.

Trial Locations (1)

Unknown

Vietnam National Cancer Institute (Hospital K), Hanoi